PLx Pharma Inc

(NASDAQ:PLXP)

Latest On PLx Pharma Inc (PLXP):

Date/Time Type Description Signal Details
2023-04-12 20:54 ESTNewsPLx Pharma intends to file for bankruptcy, inks stalking horse deal; stock +9% after hoursN/A
2023-04-11 17:35 ESTNewsPLx Pharma to be delisted from the Nasdaq on April 13N/A
2022-11-11 15:17 ESTNewsPLx Pharma GAAP EPS of -$0.30, revenue of $0.39MN/A
2022-11-11 15:17 ESTNewsPLx Pharma Non-GAAP EPS of -$0.37, revenue of $0.39MN/A
2022-11-11 15:16 ESTNewsPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptN/A
2022-08-15 20:09 ESTNewsPLx Pharma downgraded at Oppenheimer after Q2 missN/A
2022-08-12 23:41 ESTNewsPLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48MN/A
2022-08-12 23:41 ESTNewsPLx Pharma plunges 33% on wider-than-expected lossN/A
2022-08-12 23:41 ESTNewsPLx Pharma Inc. (PLXP) CEO, Natasha Giordano on Q2 2022 Results - Earnings Call TranscriptN/A
2022-06-16 06:11 ESTNewsPLx Pharma (PLXP) Investor Presentation - SlideshowN/A
2022-05-14 01:42 ESTNewsPLx Pharma Non-GAAP EPS of -$0.66 misses by $0.04, revenue of $2.08M misses by $0.45MN/A
2022-05-14 01:41 ESTNewsPLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call TranscriptN/A
2022-03-11 16:24 ESTNewsPLx Pharma GAAP EPS of -$0.73 misses by $0.02, revenue of $1.59M misses by $0.46MN/A
2022-03-11 16:24 ESTNewsPLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call TranscriptN/A
2021-12-07 16:05 ESTNewsPLx Pharma gains after Raymond James upgraded on valuationN/A
2021-11-25 02:14 ESTNewsWarning: PLXP is at high risk of performing badlyN/A
2021-11-13 02:27 ESTNewsPLx Pharma EPS beats by $0.09, beats on revenueN/A
2021-11-13 02:26 ESTNewsPLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-29 22:51 ESTNewsPLx Pharma provides Vazalore launch updateN/A
2021-09-22 03:30 ESTNewsPLx Pharma: First Commercial Launch Makes It AttractiveN/A
2021-08-26 18:16 ESTNewsPLx Pharma's Vazalore now available at retailers and e-commerce sitesN/A
2021-08-16 23:05 ESTNewsPLx Pharma Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-07 23:18 ESTNewsPLx Pharma's (PLXP) CEO Natasha Giordano on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 08:46 ESTNewsPLx Pharma EPS misses by $0.57N/A
2021-08-02 22:01 ESTNewsPLx Pharma's VAZALORE to launch in nearly 8,000 CVS stores this monthN/A
2021-07-26 20:55 ESTNewsPLx Pharma's VAZALORE to launch in over 2,400 Rite Aid stores in AugustN/A
2021-07-21 19:20 ESTNewsPLx Pharma shares jump on VAZALORE U.S. Walmart launchN/A
2021-07-21 19:15 ESTNewsPLx Pharma's VAZALORE to launch in over 8,000 Walgreens stores nationwideN/A
2021-04-10 02:53 ESTNewsProvention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst actionN/A
2021-03-16 21:45 ESTEarnings EstimateAn EPS average of -$0.76 is estimated for the 2022 year.Buy
2021-03-16 21:45 ESTEarnings EstimateAn EPS average of -$0.24 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 21:45 ESTEarnings EstimateAn EPS average of -$0.25 is estimated for the quarter ending on March 31, 2021.Buy
2021-03-14 09:22 ESTFinancialsCompany financials have been released.Neutral
2021-03-13 05:45 ESTNewsPLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-12 09:17 ESTNewsPLx Pharma EPS misses by $0.58N/A
2021-03-03 12:07 ESTNewsPLx Pharma under pressure after $63M capital raiseN/A
2021-03-02 17:41 ESTNewsPLx Pharma proposes capital raiseN/A
2021-03-02 00:31 ESTAnalyst RatingThe Analyst Target Price has increased from $9 to $12.Buy
2021-03-01 22:28 ESTNewsFDA OKs PLx Pharma's Vazalore applicationsN/A
2020-11-26 21:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 12:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $10 to $9.Neutral
2020-11-17 17:00 ESTNewsPLx Pharma EPS misses by $0.10N/A
2020-11-17 16:59 ESTNewsPLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-17 05:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 00:37 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:51 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:46 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:51 ESTFinancialsCompany financials have been released.Neutral
2020-09-03 09:28 ESTInsider TradeRita M O'Connor has directly acquired 2,120 shares and currently holds 12,970 shares.Buy
2020-09-03 09:28 ESTInsider TradeRita M O'Connor has directly acquired 4,500 shares and currently holds 10,850 shares.Buy

About PLx Pharma Inc (PLXP):

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.

PLXP Quotes by TradingView

See Advanced Chart

General

  • Name PLx Pharma Inc
  • Symbol PLXP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 8
  • Last Split Factor1:8
  • Last Split Date2017-04-20
  • Fiscal Year EndDecember
  • IPO Date2014-03-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://plxpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1333.99
  • Enterprise Value Revenue 3293.12
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.03
  • Next Year EPS Estimate -$0.76
  • Operating Margin -44230%
  • Return on Assets -37%
  • Return on Equity -192%
  • Revenue 30430
  • Earnings Per Share -$3.87
  • Revenue Per Share $0
  • Gross Profit 30430
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 222.44 million
  • EBITDA -11888050
  • PEG Ratio -0.11
  • Analyst Target Price $12
  • Book Value Per Share -$1.50
View More

Share Statistics

  • Shares Outstanding 21.79 million
  • Shares Float 18.48 million
  • % Held by Insiders 535%
  • % Held by Institutions 54.55%
  • Shares Short 668214
  • Shares Short Prior Month 620455
  • Short Ratio 4.37
  • Short % of Float 5%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 5.16
  • 52 Week High $10.38
  • 52 Week Low $1.8
  • 50 Day Moving Average 7.52
  • 200 Day Moving Average 5.23
View More

Dividends

  • Dividend Date 2017-04-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

PLx Pharma Inc (PLXP) Dividend Calendar:

PLXP's last dividend payment was made to shareholders on April 20, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

PLx Pharma Inc (PLXP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-12$N/A-$0.87-$0.29-200%
2020-09-302020-11-13$N/A-$0.40-$0.435.88%
2020-06-302020-08-14$N/A-$0.66-$0.42-59.04%
2020-03-312020-05-15$2523$0.08-$0.40120.25%
2019-12-312020-03-13$23893-$0.25-$0.4847.92%
2019-09-302019-11-08$41106$0.09-$0.50118.18%
2019-06-302019-08-09$182905-$1.10-$0.44-152.87%
2019-03-312019-05-10$317560-$2.71-$0.33-721.21%
2018-12-312019-03-08$287662$0.34-$0.37191.89%
2018-09-302018-11-09$216530-$0.39-$0.390%
2018-06-302018-08-10$167459-$0.41-$0.410%
2018-03-312018-05-11$81457$0.57-$0.45228.09%
2017-12-312018-03-23$341000-$0.90-$0.53-69.81%
2017-09-302017-11-09$62000-$0.44-$0.41-7.32%
2017-06-302017-08-10$376000-$0.36-$0.24-50%
2017-03-312017-04-17$N/A-$1.10
2016-12-312017-01-20$20000-$4.18-$2.80-49.29%
2016-09-302016-11-10$N/A-$3.60-$3.600%
2016-06-302016-08-03$N/A-$4.16-$4.282.8%
2016-03-312016-05-11$N/A-$4.48-$4.13-8.47%
2015-12-312016-03-22$171592-$4.32-$3.89-11.05%
2015-09-302015-11-16$-156000-$3.92-$3.79-3.43%
2015-06-302015-08-13$156000-$3.76-$3.44-9.3%
2015-03-312015-05-14$N/A-$0.49-$0.43-13.95%
2014-12-312015-03-24$119000-$0.38-$0.5226.92%
2014-09-302014-11-12$-169000-$0.45-$0.498.16%
2014-06-302014-08-12$169000-$3.68-$2.96-24.32%
2014-03-312014-05-12$N/A-$3.52-$1.60-120%

PLx Pharma Inc (PLXP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 1.22 million N/A N/A 513914 935513
Income Before Tax -7.98 million N/A N/A 1.5 million -2 million
Selling General Administrative 2.47 million N/A N/A 2.49 million 2.85 million
Gross Profit N/A N/A N/A N/A 23893
Ebit -8 million N/A N/A 1.67 million -3.76 million
Operating Income -3.69 million N/A N/A -3 million -3.76 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 2523 23893
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 4.6 million 1.76 million
Net Income From Continuing Operations -7.98 million N/A N/A 1.5 million -2 million
Net Income Applicable to Common Shares -8.49 million -3.63 million -6.01 million N/A -2.32 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A 2346 -2346 N/A N/A
Change to Liabilities -687244 581541 N/A N/A -137825
Total Cash Flow from Investing Activities -102000 2346 N/A N/A -132769
Net Borrowings -937500 -937500 N/A N/A -937500
Total Cash Flow from Financial Activities N/A 6.79 million -937500 N/A 541585
Change to Operating Activities 52975 74211 N/A N/A 239986
Change in Cash N/A 3.97 million -4.71 million N/A -2.75 million
Total Cash from Operating Activities -3.12 million -2.83 million -3.77 million N/A -3.16 million
Depreciation N/A 33039 31668 N/A 31560
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A 2523 16160 N/A 193732
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 369783 2.2 million N/A N/A -5.24 million
Capital Expenditures N/A N/A 2346 N/A 132769
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 16.16 million N/A N/A 10.68 million 16.93 million
Total Stockholder Equity -10.93 million N/A N/A 3.02 million -12.09 million
Other Current Liabilities 1.46 million 342175 N/A 319835 304603
Total Assets 26.62 million N/A N/A 13.7 million 18.5 million
Common Stock 13912 9156 9156 N/A 9156
Other Current Assets 2.94 million N/A N/A N/A N/A
Retained Earnings -102.15 million -94.17 million -91.04 million -85.44 million -86.94 million
Other Liabilities N/A 7.88 million 7.59 million N/A 10.22 million
Other Assets N/A 17035 73665 N/A 73665
Cash 22.45 million N/A N/A 9.29 million 14 million
Total Current Liabilities 3.54 million 3.81 million N/A 5.33 million 6.09 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 1.23 million 1.66 million 1.88 million N/A 2.08 million
Total Current Assets 22.99 million 9.62 million N/A 9.58 million 14.28 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 10.45 million -21.78 million -18.44 million N/A -14.15 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt 2.8 million N/A N/A N/A 622265
Inventory N/A 143380 N/A N/A N/A
Accounts Payable 1.46 million 612367 N/A 761588 928921

PLx Pharma Inc (PLXP) Chart:

PLx Pharma Inc (PLXP) News:

Below you will find a list of latest news for PLx Pharma Inc (PLXP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

PLx Pharma Inc (PLXP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest PLXP Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$1.89
Jun 13, 2022 7:59 PM EST130$1.89
Jun 13, 2022 7:59 PM EST7$1.89
Jun 13, 2022 7:59 PM EST29$1.895
Jun 13, 2022 7:59 PM EST2$1.9

PLx Pharma Inc (PLXP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1497504/000092189520001880/0000921895-20-001880-index.htm
2019-03-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1497504/000000000019006292/0000000000-19-006292-index.htm
2019-04-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1497504/000000000019007201/0000000000-19-007201-index.htm
2020-07-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1497504/000000000020005953/0000000000-20-005953-index.htm
2017-06-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1497504/000090571817000614/0000905718-17-000614-index.htm
2017-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000090571817000616/0000905718-17-000616-index.htm
2017-11-20SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1497504/000090571817000990/0000905718-17-000990-index.htm
2018-12-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1497504/000090571818001016/0000905718-18-001016-index.htm
2018-12-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000090571818001018/0000905718-18-001018-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000090571819000246/0000905718-19-000246-index.htm
2019-03-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1497504/000090571819000268/0000905718-19-000268-index.htm
2019-03-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000090571819000280/0000905718-19-000280-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000090571820000470/0000905718-20-000470-index.htm
2020-05-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1497504/000090571820000473/0000905718-20-000473-index.htm
2017-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000091412117001517/0000914121-17-001517-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518000101/0000921895-18-000101-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002193/0000921895-18-002193-index.htm
2018-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002259/0000921895-18-002259-index.htm
2018-08-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002261/0000921895-18-002261-index.htm
2018-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002519/0000921895-18-002519-index.htm
2018-08-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002521/0000921895-18-002521-index.htm
2018-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002522/0000921895-18-002522-index.htm
2018-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518002618/0000921895-18-002618-index.htm
2018-12-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189518003367/0000921895-18-003367-index.htm
2018-12-26PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189518003383/0000921895-18-003383-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000028/0000921895-19-000028-index.htm
2019-01-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000053/0000921895-19-000053-index.htm
2019-02-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000355/0000921895-19-000355-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000424/0000921895-19-000424-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000545/0000921895-19-000545-index.htm
2019-03-04DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000636/0000921895-19-000636-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000811/0000921895-19-000811-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000812/0000921895-19-000812-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000813/0000921895-19-000813-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000814/0000921895-19-000814-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000815/0000921895-19-000815-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000816/0000921895-19-000816-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000817/0000921895-19-000817-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000818/0000921895-19-000818-index.htm
2019-03-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000831/0000921895-19-000831-index.htm
2019-03-25S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1497504/000092189519000876/0000921895-19-000876-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000886/0000921895-19-000886-index.htm
2019-03-26DEL AMDelaying amendmenthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000899/0000921895-19-000899-index.htm
2019-03-27S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1497504/000092189519000908/0000921895-19-000908-index.htm
2019-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000996/0000921895-19-000996-index.htm
2019-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1497504/000092189519000997/0000921895-19-000997-index.htm
2019-04-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1497504/000092189519001011/0000921895-19-001011-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519001594/0000921895-19-001594-index.htm
2019-07-02DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189519001952/0000921895-19-001952-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189519002283/0000921895-19-002283-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000025/0000921895-20-000025-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000088/0000921895-20-000088-index.htm
2020-03-20PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000840/0000921895-20-000840-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000899/0000921895-20-000899-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000900/0000921895-20-000900-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000901/0000921895-20-000901-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000902/0000921895-20-000902-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000903/0000921895-20-000903-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000904/0000921895-20-000904-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000905/0000921895-20-000905-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520000906/0000921895-20-000906-index.htm
2020-04-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001041/0000921895-20-001041-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001171/0000921895-20-001171-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001269/0000921895-20-001269-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001482/0000921895-20-001482-index.htm
2020-05-29DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001635/0000921895-20-001635-index.htm
2020-06-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1497504/000092189520001880/0000921895-20-001880-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1497504/000092189520001931/0000921895-20-001931-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520002310/0000921895-20-002310-index.htm
2020-09-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1497504/000092189520002477/0000921895-20-002477-index.htm
2020-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000092189520002746/0000921895-20-002746-index.htm
2020-05-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1497504/000112329220000792/0001123292-20-000792-index.htm
2018-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380518000443/0001193805-18-000443-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380519000262/0001193805-19-000262-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380519001403/0001193805-19-001403-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380520000356/0001193805-20-000356-index.htm
2020-03-13DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1497504/000119380520000357/0001193805-20-000357-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380520000591/0001193805-20-000591-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380520001035/0001193805-20-001035-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000119380520001112/0001193805-20-001112-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000119380520001157/0001193805-20-001157-index.htm
2017-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000122783317000001/0001227833-17-000001-index.htm
2017-06-28DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000129152017000002/0001291520-17-000002-index.htm
2017-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000131351617000001/0001313516-17-000001-index.htm
2017-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000131955117000001/0001319551-17-000001-index.htm
2017-07-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000138917717000002/0001389177-17-000002-index.htm
2017-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1497504/000143774917011114/0001437749-17-011114-index.htm
2017-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000143774917011116/0001437749-17-011116-index.htm
2017-06-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1497504/000143774917011718/0001437749-17-011718-index.htm
2017-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000143774917014342/0001437749-17-014342-index.htm
2017-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774917014488/0001437749-17-014488-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000143774917014638/0001437749-17-014638-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000143774917014749/0001437749-17-014749-index.htm
2017-08-158-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000143774917014764/0001437749-17-014764-index.htm
2017-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000143774917016057/0001437749-17-016057-index.htm
2017-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1497504/000143774917016415/0001437749-17-016415-index.htm
2017-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1497504/000143774917016763/0001437749-17-016763-index.htm
2017-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774917018920/0001437749-17-018920-index.htm
2018-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774918005277/0001437749-18-005277-index.htm
2018-04-2710-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774918007987/0001437749-18-007987-index.htm
2018-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774918009524/0001437749-18-009524-index.htm
2018-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774918015162/0001437749-18-015162-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774918020177/0001437749-18-020177-index.htm
2019-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774919004386/0001437749-19-004386-index.htm
2019-04-0210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774919006284/0001437749-19-006284-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774919009360/0001437749-19-009360-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774919016122/0001437749-19-016122-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774919022041/0001437749-19-022041-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774920005044/0001437749-20-005044-index.htm
2020-04-2410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1497504/000143774920008381/0001437749-20-008381-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774920010864/0001437749-20-010864-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1497504/000143774920017893/0001437749-20-017893-index.htm
2019-04-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1497504/999999999519000607/9999999995-19-000607-index.htm
2019-04-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1497504/999999999519000610/9999999995-19-000610-index.htm
2020-07-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1497504/999999999520001717/9999999995-20-001717-index.htm
2017-08-21CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1497504/999999999717008162/9999999997-17-008162-index.htm
2019-09-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1497504/999999999719006920/9999999997-19-006920-index.htm

PLx Pharma Inc (PLXP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PLx Pharma Inc (PLXP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 535%
Institutional Ownership: 5455%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-09-01Rita M O'ConnorChief Financial OfficerBuy4,500.003.7416,837.2010,850.00https://www.sec.gov/Archives/edgar/data/1497504/000119380520001112/0001193805-20-001112-index.htm
2017-06-14Michael J ValentinoExecutive ChairmanBuy29,091.006.88200,000.63122,386.00https://www.sec.gov/Archives/edgar/data/1497504/000131955117000001/0001319551-17-000001-index.htm
2020-09-02Rita M O'ConnorChief Financial OfficerBuy2,120.003.838,126.6012,970.00https://www.sec.gov/Archives/edgar/data/1497504/000119380520001112/0001193805-20-001112-index.htm
2018-12-27Park West Asset Management LLC10% Share HolderBuy397,495.001.00397,495.001,473,218.00https://www.sec.gov/Archives/edgar/data/1497504/000090571818001018/0000905718-18-001018-index.htm
2017-06-14DAVID EMERSON JORDENActing Chief Financial OfficerBuy32,727.006.88224,998.13151,913.00https://www.sec.gov/Archives/edgar/data/1497504/000131351617000001/0001313516-17-000001-index.htm
2017-08-10Michael J ValentinoExecutive ChairmanBuy30,000.00152,386.00https://www.sec.gov/Archives/edgar/data/1497504/000143774917014638/0001437749-17-014638-index.htm
2019-05-20Michael J ValentinoExecutive ChairmanBuy44,404.005.60248,662.40196,790.00https://www.sec.gov/Archives/edgar/data/1497504/000092189519001594/0000921895-19-001594-index.htm
2020-08-20Rita M O'ConnorChief Financial OfficerBuy2,300.003.778,665.712,300.00https://www.sec.gov/Archives/edgar/data/1497504/000092189520002310/0000921895-20-002310-index.htm
2020-08-21Rita M O'ConnorChief Financial OfficerBuy4,050.003.9716,090.656,350.00https://www.sec.gov/Archives/edgar/data/1497504/000092189520002310/0000921895-20-002310-index.htm
2017-06-14GARY L MOSSMANChief Operating OfficerBuy7,273.006.8850,001.8878,255.00https://www.sec.gov/Archives/edgar/data/1497504/000122783317000001/0001227833-17-000001-index.htm